Accuray Inc. (ARAY) is a reputable American corporation that specializes in radiation oncology. It is headquartered in Sunnyvale, California, and has built its impressive reputation on striving to create a healthier and extended future for cancer patients across the globe. Founded in 1990, this public conglomerate is listed on the NASDAQ Stock Market and has substantially expanded its scope over the last three decades.
Accuray Inc. is recognized for delivering innovative, technologically advanced systems that provide novel solutions to radiation oncology. They designed and manufacture two primary products; the CyberKnife Systems and the TomoTherapy Systems. Both these systems use sophisticated software, advanced imaging, and precision radiation delivery to target and treat tumors accurately.
The CyberKnife Systems use robotic technology to deliver radiation to the tumor precisely from virtually any angle. This highly flexible system delivers high doses of radiation from a large number of angles with excellent precision, sparing healthy tissue and organs surrounding the tumor.
On the other hand, the TomoTherapy Systems offer integrated CT imaging to enhance efficiency and precision. It holds the honor of being the world's first and only system to seamlessly integrate 3D daily imaging with intensity-modulated radiation therapy (IMRT), setting a new standard in precision and accuracy in radiation therapy.
Accuray Inc. is dedicated to personalizing patient treatments, particularly in cases of cancer where patients' needs vary dramatically. Underpinning their approach is a steadfast commitment to clinical excellence and technological innovation, enhanced by a comprehensive framework of support services including training, technical support, and maintenance.
With a global footprint extending across 50 countries, Accuray Inc. has established strong international collaborations and dramatically broadened its reach. The company continually invests in research and development, seeking out innovative strategies to improve the efficacy of radiotherapy and radiosurgery treatments, enhance patient outcomes, and ultimately push the boundaries of cancer treatment.
In conclusion, Accuray Inc. is a global leader in radiation oncology, making significant contributions to advancing cancer treatment. Their patient-first philosophy and continuous pursuit of innovation underscore their mission to create a future where cancer can be conquered effectively and with minimal side effects.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Accuray Director Richard A. Meier was granted 75,000 restricted stock units (RSUs) and 75,000 non-qualified stock options on October 5, 2026, as revealed in a Form 4 filing with the SEC. Both awards vest in three equal annual installments starting one year from the grant date. Following these transactions, Meier directly holds 75,000 RSUs and 75,000 stock options in Accuray Inc (NASDAQ:ARAY).
Accuray Incorporated has announced the appointment of Richard A. ("Randy") Meier to its board of directors and Compensation Committee, effective October 6, 2026. Mr. Meier brings over 30 years of executive leadership experience in the healthcare and medical technology sectors, including prior CEO and CFO roles. His expertise spans transformational growth initiatives, strategic acquisitions, and operational restructurings across global healthcare organizations.
Accuray and Samsung NeuroLogica are advancing their collaboration to integrate volumetric imaging capabilities into the CyberKnife® System, aiming to enhance treatment efficiency and decision-making in radiation oncology. This partnership combines Samsung NeuroLogica's expertise in mobile CT with Accuray's precision treatment delivery. Leading clinicians highlight the potential for improved visualization of patient anatomy and adaptive treatment, reinforcing the importance of this innovation for various cancer treatments.